{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:57:56Z","timestamp":1795100276711,"version":"4.10.3"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.diabet.2023.101470","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T08:36:15Z","timestamp":1693384575000},"page":"101470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4135-5436","authenticated-orcid":false,"given":"Marine","family":"Monney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois R","family":"Jornayvaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Gariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2023.101470_bib0001","unstructured":"Dementia [Internet]. [cit\u00e9 23 may 2022]. Disponible sur: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"10.1016\/j.diabet.2023.101470_bib0002","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.diabet.2023.101470_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2023.101470_bib0004","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc15-0491","article-title":"Risk of dementia in seniors with newly diagnosed diabetes: a population-based study","volume":"38","author":"Haroon","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101470_bib0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamapsychiatry.2015.0082","article-title":"Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study","volume":"72","author":"Katon","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.diabet.2023.101470_bib0006","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11892-014-0487-z","article-title":"Diabetes mellitus and dementia","volume":"14","author":"Ninomiya","year":"2014","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabet.2023.101470_bib0007","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2174\/1573399815666190129155654","article-title":"Pathophysiological mechanisms linking type 2 diabetes and dementia: review of evidence from clinical, translational and epidemiological research","volume":"15","author":"Bello-Chavolla","year":"2019","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabet.2023.101470_bib0008","article-title":"Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines","volume":"2013","author":"Makki","year":"2013","journal-title":"ISRN Inflamm"},{"key":"10.1016\/j.diabet.2023.101470_bib0009","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/18715273113126660137","article-title":"Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation","volume":"13","author":"Kamal","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.diabet.2023.101470_bib0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.diabet.2023.101470_bib0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuint.2012.12.016","article-title":"Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease","volume":"62","author":"Taylor","year":"2013","journal-title":"Neurochem Int"},{"key":"10.1016\/j.diabet.2023.101470_bib0012","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/1535370215576313","article-title":"Parkinson's disease and enhanced inflammatory response","volume":"240","author":"Stojkovska","year":"2015","journal-title":"Exp Biol Med Maywood NJ"},{"key":"10.1016\/j.diabet.2023.101470_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00401-003-0766-2","article-title":"Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains","volume":"106","author":"Imamura","year":"2003","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.diabet.2023.101470_bib0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuropharm.2017.12.001","article-title":"Insulin-mediated synaptic plasticity in the CNS: anatomical, functional and temporal contexts","volume":"136","author":"Ferrario","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.diabet.2023.101470_bib0015","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3390\/cells10051236","article-title":"Insulin resistance and diabetes mellitus in Alzheimer's disease","volume":"10","author":"Burillo","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.diabet.2023.101470_bib0016","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00592-013-0546-y","article-title":"Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans","volume":"51","author":"Heni","year":"2014","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2023.101470_bib0017","first-page":"125","article-title":"Diabetes mellitus and blood-brain barrier dysfunction: an overview","volume":"02","author":"Prasad","year":"2014","journal-title":"J Pharmacovigil"},{"key":"10.1016\/j.diabet.2023.101470_bib0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1096\/fj.06-7703com","article-title":"Amyloid beta oligomers induce impairment of neuronal insulin receptors","volume":"22","author":"Zhao","year":"2008","journal-title":"FASEB"},{"key":"10.1016\/j.diabet.2023.101470_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbr.2017.11.015","article-title":"Diabetes mellitus and Alzheimer's disease: GSK-3\u03b2 as a potential link","volume":"339","author":"Zhang","year":"2018","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.diabet.2023.101470_bib0020","unstructured":"(Pre)diabetes, brain aging, and cognition | Elsevier Enhanced Reader [Internet]. [cit\u00e9 12 d\u00e9c 2022]. Disponible sur: https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S0925443908002524?token=F425B21093C1F6234EFBE639E52509E47ABFA998A6EF738FC4C1CBE76AAC90F3FA363314605565BF37A0761E6F4C7FEC&originRegion=eu-west-1&originCreation=20221212145438."},{"key":"10.1016\/j.diabet.2023.101470_bib0021","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J Alzheimers Dis JAD"},{"key":"10.1016\/j.diabet.2023.101470_bib0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma \u03b2-amyloid in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J Alzheimers Dis JAD"},{"key":"10.1016\/j.diabet.2023.101470_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.diabet.2023.101470_bib0024","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2337\/db14-1000","article-title":"Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes","volume":"64","author":"Zhang","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2023.101470_bib0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/joim.12000","article-title":"Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study","volume":"273","author":"Lin","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.diabet.2023.101470_bib0026","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2009.460","article-title":"Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus","volume":"301","author":"Whitmer","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2023.101470_bib0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcjd.2015.09.006","article-title":"Diabetes, dementia and hypoglycemia","volume":"40","author":"Meneilly","year":"2016","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.diabet.2023.101470_bib0028","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuroscience.2013.07.009","article-title":"Molecular links between Alzheimer's disease and diabetes mellitus","volume":"250","author":"Yang","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.diabet.2023.101470_bib0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11010-019-03553-4","article-title":"AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease","volume":"459","author":"Prasad","year":"2019","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.diabet.2023.101470_bib0030","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1111\/ejn.15502","article-title":"Potential new therapeutic target for Alzheimer's disease: glucagon-like peptide-1","volume":"54","author":"Liu","year":"2021","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.diabet.2023.101470_bib0031","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fnagi.2017.00345","article-title":"Insulin resistance and Alzheimer's disease: bioenergetic linkages","volume":"9","author":"Neth","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.diabet.2023.101470_bib0032","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.euroneuro.2014.01.023","article-title":"Brain imaging in type 2 diabetes","volume":"24","author":"Brundel","year":"2014","journal-title":"Eur Neuropsychopharmacol J"},{"key":"10.1016\/j.diabet.2023.101470_bib0033","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/ijms23020739","article-title":"GLP-1a: going beyond traditional use","volume":"23","author":"Laurindo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2023.101470_bib0034","unstructured":"Glucagon.com [Internet]. [cit\u00e9 15 d\u00e9c 2022]. Disponible sur: https:\/\/www.glucagon.com\/glp1.html."},{"key":"10.1016\/j.diabet.2023.101470_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","article-title":"Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?","volume":"118","author":"Bassil","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.diabet.2023.101470_bib0036","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/ijms18112493","article-title":"The Role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain","volume":"18","author":"Bae","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2023.101470_bib0037","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.diabet.2023.101470_bib0038","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.diabet.2023.101470_bib0039","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabet.2023.101470_bib0040","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"H\u00f6lscher","year":"2014","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2023.101470_bib0041","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.diabet.2023.101470_bib0047","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.diabet.2023.101470_bib0046","first-page":"141","article-title":"12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with type-2 diabetes mellitus","volume":"10","author":"Perna","year":"2018","journal-title":"Clin Pharmacol Adv Appl"},{"key":"10.1016\/j.diabet.2023.101470_bib0042","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.diabet.2023.101470_bib0045","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2337\/dc18-2584","article-title":"Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies","volume":"42","author":"Zhang","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101470_bib0043","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int J Obes"},{"key":"10.1016\/j.diabet.2023.101470_bib0044","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020734","article-title":"Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabet.2023.101470_bib0060","doi-asserted-by":"crossref","DOI":"10.2337\/dc21-2064","article-title":"Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study","author":"Cheng","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101470_bib0048","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2023.101470_bib0049","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J Park Dis"},{"key":"10.1016\/j.diabet.2023.101470_bib0050","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2023.101470_bib0051","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A Pilot study of exenatide actions in Alzheimer's disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.diabet.2023.101470_bib0052","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/JCP.0000000000001409","article-title":"Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores through increased perceived stress levels","volume":"41","author":"Eren-Yazicioglu","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.diabet.2023.101470_bib0053","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.diabet.2023.101470_bib0054","doi-asserted-by":"crossref","first-page":"e12268","DOI":"10.1002\/trc2.12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"10.1016\/j.diabet.2023.101470_bib0058","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabet.2023.101470_bib0059","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.diabet.2023.101470_bib0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101470_bib0056","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101470_bib0057","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101470_bib0061","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101470_bib0062","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/dom.15009","volume":"25","author":"Nguyen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101470_bib0063","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","article-title":"Alzheimer's disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement Transl Res Clin Interv"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363623000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363623000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:59:22Z","timestamp":1761130762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363623000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1262363623000526"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2023.101470","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2023.101470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101470"}}